What are the contraindications for prescribing phosphodiesterase‑5 (PDE5) inhibitors?

Contraindications for PDE5 Inhibitors

PDE5 inhibitors are absolutely contraindicated in patients taking any form of nitrate medication, including organic nitrates, nitrate-containing compounds, and recreational "poppers," because the combination causes life-threatening synergistic hypotension. 1, 2

Absolute Contraindications

Nitrate Use

• Concurrent nitrate therapy is the single most critical contraindication—this includes nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational nitrites (amyl nitrite/"poppers") 2, 3
• The interaction produces profound vasodilation and severe hypotension that can be fatal 4, 5
• Timing restrictions after PDE5i use:
  • Short-acting agents (sildenafil, vardenafil, avanafil): nitrates may be given ≥24 hours after the last dose 2, 4
  • Long-acting agents (tadalafil): nitrates may be given ≥48 hours after the last dose 2, 4
• Patients currently on nitrates who wish to use PDE5i should be evaluated to determine whether nitrate therapy can be safely discontinued 2

Relative Contraindications & Cautions

Alpha-Blocker Therapy

• Concomitant alpha-blocker use (for hypertension or benign prostatic hypertrophy) increases the risk of orthostatic hypotension 6, 4
• Precautions are necessary for all PDE5 inhibitors when combined with alpha-blockers 4
• The interaction appears less clinically relevant in patients on long-term, stable alpha-blocker therapy 4
• Tamsulosin may be safer than other alpha-blockers when combined with PDE5i 7
• Use the lowest effective doses of both medications when combining 7

Severe Hepatic or Renal Impairment

• Severe renal disease: PDE5i use is generally not recommended 6
• Severe hepatic disease: PDE5i use is generally not recommended 6
• Mild to moderate hepatic or renal impairment: start with lower doses due to delayed drug metabolism 6
• For sildenafil specifically, initiate at 25 mg in patients with severe renal or hepatic disease 1

Bleeding Disorders & Anticoagulation

• Patients on anticoagulant therapy or with bleeding disorders should use vacuum erection devices (an alternative to PDE5i) with caution, though this is not a direct PDE5i contraindication 6
• The evidence does not establish PDE5i as contraindicated in bleeding disorders, but caution is warranted

Specific Medical Conditions Requiring Evaluation

• Retinitis pigmentosa: should be identified before initiating therapy as it affects safety considerations 1
• Peptic ulcer disease: requires assessment before starting PDE5i 1
• History of priapism: warrants careful consideration, as PDE5i show significant pharmacovigilance signals for priapism 8

Important Clinical Caveats

Cardiovascular Disease

• PDE5i are not contraindicated in stable cardiovascular disease, hypertension, or coronary artery disease 3, 5
• They produce only modest blood pressure reductions (sildenafil 100 mg: -3.7/-3.6 mmHg; vardenafil 20 mg: -7.5/-8 mmHg; tadalafil 20 mg: -1.6/-0.8 mmHg) 7
• The additive effect with most antihypertensive drugs (beta-blockers, ACE inhibitors, ARBs, calcium antagonists, diuretics) is modest and generally well-tolerated 4, 5
• Statistical analyses show PDE5i do not increase myocardial infarction or death rates compared to placebo 4

Spinal Cord Injury

• Use with caution and consider lower initial doses 6

Common Pitfalls to Avoid

• Do not assume all cardiovascular disease is a contraindication—only concurrent nitrate use is absolute 3, 5
• Do not overlook recreational nitrite use ("poppers")—patients may not volunteer this information 2
• Do not combine with alpha-blockers without dose adjustment—start both medications at the lowest effective doses 7
• Do not prescribe without screening for nitrate use—this is the most critical safety check 1, 2